APA (7th ed.) Citation

MQ, C., TJ, Z., Y, F., X, S., YH, J., J, Q., & JD, Z. (2025). Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: A case report. Frontiers in immunology, 16, 1566035. https://doi.org/10.3389/fimmu.2025.1566035

Chicago Style (17th ed.) Citation

MQ, Chu, Zhang TJ, Feng Y, Shao X, Ji YH, Qian J, and Zhou JD. "Successful Treatment of Primary Refractory DLBCL/HGBL - MYC/BCL2 Transformed from FL Using Glofitamab: A Case Report." Frontiers in Immunology 16 (2025): 1566035. https://doi.org/10.3389/fimmu.2025.1566035.

MLA (9th ed.) Citation

MQ, Chu, et al. "Successful Treatment of Primary Refractory DLBCL/HGBL - MYC/BCL2 Transformed from FL Using Glofitamab: A Case Report." Frontiers in Immunology, vol. 16, 2025, p. 1566035, https://doi.org/10.3389/fimmu.2025.1566035.